220 related articles for article (PubMed ID: 34681738)
1. Clinical Guidelines and New Molecular Targets for Cutaneous Lymphomas.
Sugaya M
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681738
[TBL] [Abstract][Full Text] [Related]
2. BCL2 and JUNB abnormalities in primary cutaneous lymphomas.
Mao X; Orchard G; Lillington DM; Child FJ; Vonderheid EC; Nowell PC; Bagot M; Bensussan A; Russell-Jones R; Young BD; Whittaker SJ
Br J Dermatol; 2004 Sep; 151(3):546-56. PubMed ID: 15377339
[TBL] [Abstract][Full Text] [Related]
3. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions.
Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
J Am Acad Dermatol; 2014 Feb; 70(2):223.e1-17; quiz 240-2. PubMed ID: 24438970
[TBL] [Abstract][Full Text] [Related]
4. CD30+ neoplasms of the skin.
Duvic M
Curr Hematol Malig Rep; 2011 Dec; 6(4):245-50. PubMed ID: 21850406
[TBL] [Abstract][Full Text] [Related]
5. Upregulation of inhibitory signaling receptor programmed death marker-1 (PD-1) in disease evolution from cutaneous lymphoid dyscrasias to mycosis fungoides and Sezary's syndrome.
Nguyen GH; Olson LC; Magro CM
Ann Diagn Pathol; 2017 Jun; 28():54-59. PubMed ID: 28648940
[TBL] [Abstract][Full Text] [Related]
6. Defucosylated anti CC chemokine receptor 4 monoclonal antibody combined with immunomodulatory cytokines: a novel immunotherapy for aggressive/refractory Mycosis fungoides and Sezary syndrome.
Yano H; Ishida T; Inagaki A; Ishii T; Ding J; Kusumoto S; Komatsu H; Iida S; Inagaki H; Ueda R
Clin Cancer Res; 2007 Nov; 13(21):6494-500. PubMed ID: 17975162
[TBL] [Abstract][Full Text] [Related]
7. Guidelines for phototherapy of mycosis fungoides and Sézary syndrome: A consensus statement of the United States Cutaneous Lymphoma Consortium.
Olsen EA; Hodak E; Anderson T; Carter JB; Henderson M; Cooper K; Lim HW
J Am Acad Dermatol; 2016 Jan; 74(1):27-58. PubMed ID: 26547257
[TBL] [Abstract][Full Text] [Related]
8. European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome - Update 2017.
Trautinger F; Eder J; Assaf C; Bagot M; Cozzio A; Dummer R; Gniadecki R; Klemke CD; Ortiz-Romero PL; Papadavid E; Pimpinelli N; Quaglino P; Ranki A; Scarisbrick J; Stadler R; Väkevä L; Vermeer MH; Whittaker S; Willemze R; Knobler R
Eur J Cancer; 2017 May; 77():57-74. PubMed ID: 28365528
[TBL] [Abstract][Full Text] [Related]
9. Novel biomarkers, dysregulated epigenetics, and therapy in cutaneous T-cell lymphoma.
Wong HK
Discov Med; 2013 Sep; 16(87):71-8. PubMed ID: 23998443
[TBL] [Abstract][Full Text] [Related]
10. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers.
Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
J Am Acad Dermatol; 2014 Feb; 70(2):205.e1-16; quiz 221-2. PubMed ID: 24438969
[TBL] [Abstract][Full Text] [Related]
11. Monoclonal antibodies against cutaneous T-cell lymphomas.
Alaibac M
Expert Opin Biol Ther; 2017 Dec; 17(12):1503-1510. PubMed ID: 28829215
[TBL] [Abstract][Full Text] [Related]
12. CCR4 in cutaneous T-cell lymphoma: Therapeutic targeting of a pathogenic driver.
Nicolay JP; Albrecht JD; Alberti-Violetti S; Berti E
Eur J Immunol; 2021 Jul; 51(7):1660-1671. PubMed ID: 33811642
[TBL] [Abstract][Full Text] [Related]
13. The expression of cell adhesion molecule 1 and its splicing variants in Sézary cells and cell lines from cutaneous T-cell lymphoma.
Yamaguchi M; Morizane S; Hamada T; Miyake T; Sugaya M; Iwata H; Fujii K; Haramoto-Shiratsuki R; Nakagawa Y; Miura M; Ohshima K; Morishita K; Takahashi T; Imada M; Okada K; Uehara J; Sowa-Osako J; Iwatsuki K
J Dermatol; 2019 Nov; 46(11):967-977. PubMed ID: 31515833
[TBL] [Abstract][Full Text] [Related]
14. The Microenvironment's Role in Mycosis Fungoides and Sézary Syndrome: From Progression to Therapeutic Implications.
Pileri A; Guglielmo A; Grandi V; Violetti SA; Fanoni D; Fava P; Agostinelli C; Berti E; Quaglino P; Pimpinelli N
Cells; 2021 Oct; 10(10):. PubMed ID: 34685762
[TBL] [Abstract][Full Text] [Related]
15. C-C chemokine receptor 4 expression in CD8+ cutaneous T-cell lymphomas and lymphoproliferative disorders, and its implications for diagnosis and treatment.
Geller S; Hollmann TJ; Horwitz SM; Myskowski PL; Pulitzer M
Histopathology; 2020 Jan; 76(2):222-232. PubMed ID: 31355940
[TBL] [Abstract][Full Text] [Related]
16. Expression and activity of IL-17 in cutaneous T-cell lymphomas (mycosis fungoides and Sezary syndrome).
Cirée A; Michel L; Camilleri-Bröet S; Jean Louis F; Oster M; Flageul B; Senet P; Fossiez F; Fridman WH; Bachelez H; Tartour E
Int J Cancer; 2004 Oct; 112(1):113-20. PubMed ID: 15305382
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and tolerability of currently available therapies for the mycosis fungoides and Sezary syndrome variants of cutaneous T-cell lymphoma.
Whittaker SJ; Foss FM
Cancer Treat Rev; 2007 Apr; 33(2):146-60. PubMed ID: 17275192
[TBL] [Abstract][Full Text] [Related]
18. Evolving insights in the pathogenesis and therapy of cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome).
Wong HK; Mishra A; Hake T; Porcu P
Br J Haematol; 2011 Oct; 155(2):150-66. PubMed ID: 21883142
[TBL] [Abstract][Full Text] [Related]
19. EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome.
Trautinger F; Knobler R; Willemze R; Peris K; Stadler R; Laroche L; D'Incan M; Ranki A; Pimpinelli N; Ortiz-Romero P; Dummer R; Estrach T; Whittaker S
Eur J Cancer; 2006 May; 42(8):1014-30. PubMed ID: 16574401
[TBL] [Abstract][Full Text] [Related]
20. [Primary cutaneous lymphoma-a case series of 163 patients].
Nashan D; Friedrich CM; Geissler E; Schmitt-Graeff A; Klein F; Meiss F
Hautarzt; 2018 Dec; 69(12):1014-1020. PubMed ID: 29881891
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]